A myosin hypertrophic cardiomyopathy mutation disrupts the super-relaxed state and boosts contractility by enhanced actin attachment
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Hypertrophic cardiomyopathy (HCM) is a leading cause of cardiac failure among individuals under 35. Many genetic mutations that cause HCM enhance ventricular systolic function, suggesting that these HCM mutations are hypercontractile. Among the most common causes of HCM are mutations in the gene MYH7, which encodes for β-cardiac myosin, the principal human ventricular myosin. Previous work has demonstrated that, for purified myosins, some MYH7 mutations are gain-of-function while others cause reduced function, so how they lead to enhanced contractility is not clear. Here, we have characterized the mechanics and kinetics of the severe HCM-causing mutation M493I. Motility assays demonstrate a 70% reduction of actin filament gliding velocities on M493I-coated surfaces relative to WT. This mutation slows ADP release from actomyosin·ADP 5-fold without affecting phosphate release or ATP binding. Yet it enhances steady-state ATPase V max 2-fold. Through single-molecule mechanical studies, we find that M493I myosin has a normal working stroke of 5 nm but a significantly prolonged actin attachment duration. Under isometric feedback, M493I myosins produce high, sustained force, with an actin detachment rate that is less sensitive to force than that of WT myosin. We also report direct measurement of the equilibrium state of the super-relaxed to disordered relaxed (SRX-DRX) regulatory transition and show its disruption in M493I, with a concomitant enhancement to actin attachment kinetics. Together, these data demonstrate that enhanced myosin binding from inhibition of myosin’s off state, combined with slow ADP release and enhanced force production, underlie the enhanced function and etiology of this HCM mutation.
Significance Statement
Hypertrophic cardiomyopathy (HCM) is a leading genetic cause of sudden cardiac death in young individuals. Although often described as a hypercontractile disease, the molecular basis for this remains unclear, especially for mutations with inhibitory effects in various in vitro assays. We show that the severe HCM mutation M493I in β-cardiac myosin slows ADP release yet enhances force output and actin attachment through multiple mechanisms, including disrupted autoinhibition via the super-relaxed state. Our findings unify seemingly contradictory biophysical changes into a coherent mechanistic model and support the hypothesis that increased myosin head availability, rather than enhanced individual kinetics alone, underlies HCM hypercontractility.
